rel-1,1-Dimethylethyl (6R,8aS)-6-ethynylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate | 924912-18-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: rel-1,1-Dimethylethyl (6R,8aS)-6-ethynylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate
• 英文别名: tert-butyl (6R,8aS)-6-ethynyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxylate
• CAS: 924912-18-5
• 化学式: C₁₄H₂₂N₂O₂
• 分子量: 250.34
• InChiKey: ATPOFVIVORZCSS-RYUDHWBXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Acetylenic piperazines as metabotropic glutamate receptor antagonists
  申请人：Edwards Louise

  公开号：US20070037817A1

  公开（公告）日：2007-02-15

  The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar 1 , A, B, R 1 , m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR 5 mediated disorders.

  该发明涉及公式I的化合物或其药用可接受的盐或溶剂，其中Ar1、A、B、R1、m和n如描述中所定义。该发明还包括药物组合物和用途，以及制备这些化合物的方法，以及治疗mGluR 5介导的疾病的医疗方法。
• Bicyclic piperazines as metabotropic glutatmate receptor antagonists
  申请人：Edwards Louise

  公开号：US20070037816A1

  公开（公告）日：2007-02-15

  The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar 1 , A, Hy, R 1 , m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR5-mediated disorders.

  该发明涉及公式I的化合物或其药用可接受的盐或溶剂化合物：其中Ar1、A、Hy、R1、m和n如描述中所定义。该发明还包括药物组合物、使用方法以及制备这些化合物的方法，以及治疗mGluR5介导的疾病的医疗方法。
• Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists
  申请人：Edwards Louise

  公开号：US20080194571A1

  公开（公告）日：2008-08-14

  The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar 1 , A, B, R 1 , m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR 5 mediated disorders.

  本发明涉及公式I化合物或其药学上可接受的盐或溶剂：其中Ar1，A，B，R1，m和n如描述中所定义。本发明还包括药物组合物和使用以及制备该化合物的方法，以及治疗mGluR5介导的疾病的医疗方法。
• Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists
  申请人：Edwards Louise

  公开号：US20080312240A1

  公开（公告）日：2008-12-18

  The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar 1 , A, Hy, R 1 , m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR5-mediated disorders.

  本发明涉及化合物I的公式或其药学上可接受的盐或溶剂：其中Ar1、A、Hy、R1、m和n如说明书所定义。本发明还包括制备该化合物的制剂、用途和方法，以及治疗mGluR5介导的疾病的医疗方法。
• [EN] BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS<br/>[FR] PIPERAZINES BICYCLIQUES EN TANT QU'AGENTS ANTAGONISTES DE RECEPTEUR DE GLUTAMATE METABOTROPIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2007021574A1

  公开（公告）日：2007-02-22

  [EN] The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar₁, A Hy, R₁, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR5-mediated disorders.
  [FR] L'invention concerne des composés de formule I ou des sels pharmaceutiquement acceptables ou des solvates de ceux-ci: où Ar₁, A Hy, R₁, m et n sont tels que définis dans la description. L'invention porte également sur des compositions pharmaceutiques et des utilisations de celles-ci, sur des procédés de fabrication desdits composés ainsi que sur des procédés de traitement médical de troubles médiés par mGluR5.